Annual report pursuant to Section 13 and 15(d)

ORGANIZATION AND BUSINESS (Details)

v3.22.1
ORGANIZATION AND BUSINESS (Details)
12 Months Ended
Oct. 25, 2021
USD ($)
shares
Feb. 21, 2020
shares
Feb. 11, 2020
shares
Dec. 31, 2021
USD ($)
Facility
Product
shares
Dec. 31, 2020
USD ($)
shares
Organization and Business [Abstract]          
Number of plasma collection facilities under approval and development | Facility       10  
Number of FDA-licensed plasma collection facilities | Facility       5  
Number of FDA approved product | Product       3  
Working capital       $ 178,400,000  
Cash and cash equivalents       51,100,000  
Common stock shares sold during the period (in shares) | shares 57,500,000        
Proceeds from issuance of common stock, net of offering expenses $ 53,800,000     121,144,103 $ 131,195,291
Underwritten Public Offering [Member]          
Organization and Business [Abstract]          
Proceeds from issuance of common stock, net of offering expenses       88,700,000  
Sale Agreement [Member] | Underwritten Public Offering [Member]          
Organization and Business [Abstract]          
Proceeds from issuance of common stock, net of offering expenses       $ 121,100,000  
Common Stock [Member]          
Organization and Business [Abstract]          
Common stock shares sold during the period (in shares) | shares       90,846,029 45,562,907
Common Stock [Member] | Underwritten Public Offering [Member]          
Organization and Business [Abstract]          
Common stock shares sold during the period (in shares) | shares   3,525,000 23,500,000 90,846,029